DRL unveils anti-cancer drug in U.S.

Dr. Reddy’s Laboratories has unveiled Capecitabine Tablets, USP in the U.S market. The drug is a therapeutic equivalent generic version of Xeloda (capecitabine) Tablets, used in the treatment of certain types of cancers.

Xeloda is a trademark of Hoffmann-La Roche Inc. The drug is indicated to treat colon, colorectal and breast cancers.

The Xeloda brand and generic had U.S. sales of approximately $90 million MAT for the most recent twelve months ended October 2020, Dr. Reddy’s said citing IQVIA Health numbers.

Stating that the product had been unveiled following approval from the U.S. Food and Drug Administration, a release said Dr. Reddy’s Capecitabine Tablets, USP are available in 150 mg and 500 mg strengths in bottle count sizes of 60 and 120, respectively. Shares of Dr. Reddy’s fell 2.17% to ₹4,594 apiece on Wednesday.

You have reached your limit for free articles this month.

Subscription Benefits Include

Today’s Paper

Find mobile-friendly version of articles from the day’s newspaper in one easy-to-read list.

Unlimited Access

Enjoy reading as many articles as you wish without any limitations.

Personalised recommendations

A select list of articles that match your interests and tastes.

Faster pages

Move smoothly between articles as our pages load instantly.


A one-stop-shop for seeing the latest updates, and managing your preferences.


We brief you on the latest and most important developments, three times a day.

Support Quality Journalism.

*Our Digital Subscription plans do not currently include the e-paper, crossword and print.


Source link

Leave a Reply

Your email address will not be published. Required fields are marked *